Literature DB >> 26201633

Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy.

Chia-Yang Hsu1,2,3, Yun-Hsuan Lee1,3, Yi-Hsiang Huang1,3, Cheng-Yuan Hsia1,4,3, Chien-Wei Su1,3, Han-Chieh Lin1,3, Rheun-Chuan Lee5,3, Yi-You Chiou5,3, Fa-Yauh Lee1,3, Teh-Ia Huo6,7, Shou-Dong Lee1,3.   

Abstract

PURPOSE: Ascites may develop in patients with hepatocellular carcinoma (HCC) with coexisting liver cirrhosis. Few studies had specifically evaluated the role of ascites in HCC. This study investigated its prevalence, associated factors, prognostic impact, and staging strategy in a large HCC patient cohort. PATIENTS AND METHODS: A total of 2,203 HCC patients were analyzed. The grading of ascites was according to the European Association for the Study of Liver. The prognostic ability of the Cancer of the liver Italian Program (CLIP), Barcelona Clinic Liver Cancer, Japan Integrated Scoring system, and Taipei Integrated Scoring system in HCC patients with ascites was compared using the Akaike information criterion (AIC).
RESULTS: Ascites was present in 498 (23%) patients at diagnosis. Grades 1, 2, and 3 ascites were found in 13, 5, and 5% of the patients, respectively. The severity of ascites significantly correlated with hyperbilirubinemia, hypoalbuminemia, hyponatremia, prothrombin time (PT) prolongation, and renal insufficiency (all p < 0.001). Large tumor burden and more frequent vascular invasion were often observed in patients with more severe ascites (both p < 0.001). In the Cox proportional hazard model, ascites was identified as an independent prognostic predictor with 80-94% increased risk of mortality (p < 0.001). Among HCC patients with ascites, the CLIP system had the lowest AIC value.
CONCLUSIONS: Ascites is often seen in HCC patients and is associated with both tumoral and cirrhosis factors and decreased long-term survival. The CLIP staging system is a more feasible prognostic model for HCC patients with ascites. The optimal treatment strategy for these patients remains to be investigated.

Entities:  

Keywords:  Ascites; Hepatocellular carcinoma; Liver cirrhosis; MELD

Year:  2012        PMID: 26201633     DOI: 10.1007/s12072-011-9338-z

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  39 in total

1.  A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System.

Authors:  Chia-Yang Hsu; Yi-Hsiang Huang; Cheng-Yuan Hsia; Chien-Wei Su; Han-Chieh Lin; Che-Chuan Loong; Yi-You Chiou; Jen-Huey Chiang; Pui-Ching Lee; Teh-Ia Huo; Shou-Dong Lee
Journal:  J Hepatol       Date:  2010-03-31       Impact factor: 25.083

Review 2.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

Review 3.  Estimating kidney function in adults using formulae.

Authors:  Edmund J Lamb; Charles R V Tomson; Paul J Roderick
Journal:  Ann Clin Biochem       Date:  2005-09       Impact factor: 2.057

4.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

Review 5.  A comparison of goodness-of-fit tests for the logistic regression model.

Authors:  D W Hosmer; T Hosmer; S Le Cessie; S Lemeshow
Journal:  Stat Med       Date:  1997-05-15       Impact factor: 2.373

6.  Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma.

Authors:  Ju Dong Yang; W Ray Kim; Ritika Coelho; Teresa A Mettler; Joanne T Benson; Schuyler O Sanderson; Terry M Therneau; Bohyun Kim; Lewis R Roberts
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-08       Impact factor: 11.382

7.  Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.

Authors:  Masatoshi Kudo; Hobyung Chung; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

8.  The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy.

Authors:  Teh-Ia Huo; Han-Chieh Lin; Yi-Hsiang Huang; Jaw-Ching Wu; Jen-Huei Chiang; Pui-Ching Lee; Shou-Dong Lee
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

9.  Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels.

Authors:  P Tangkijvanich; N Anukulkarnkusol; P Suwangool; S Lertmaharit; O Hanvivatvong; P Kullavanijaya; Y Poovorawan
Journal:  J Clin Gastroenterol       Date:  2000-12       Impact factor: 3.062

10.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  13 in total

1.  Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Authors:  Chuan Chen; Dong-Ping Chen; Yan-Yan Gu; Liang-Hao Hu; Dan Wang; Jin-Huan Lin; Zhao-Shen Li; Jing Xu; Ge Wang
Journal:  Tumour Biol       Date:  2015-04-02

2.  A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Hao-Jan Lei; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  Dig Dis Sci       Date:  2019-10-28       Impact factor: 3.199

3.  Using serum α-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff?

Authors:  Chia-Yang Hsu; Po-Hong Liu; Yun-Hsuan Lee; Cheng-Yuan Hsia; Yi-Hsiang Huang; Han-Chieh Lin; Yi-You Chiou; Fa-Yauh Lee; Teh-Ia Huo
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

4.  Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models.

Authors:  You Zhou; Chao Fu; Yidi Kong; Desi Pan; Yanan Wang; Shengjian Huang; Zhibin Li; Zhiqiang Ning; Xianping Lu; Song Shan; Lijun Xin
Journal:  Anticancer Drugs       Date:  2019-10       Impact factor: 2.248

5.  Albumin-to-Alkaline Phosphatase Ratio Associates with Good Prognosis of Hepatitis B Virus-Positive HCC Patients.

Authors:  Qun Li; Zhuozhen Lyu; Liguang Wang; Feifei Li; Zhen Yang; Wanhua Ren
Journal:  Onco Targets Ther       Date:  2020-03-20       Impact factor: 4.147

6.  Survival of Patients with Hepatocellular Carcinoma in Renal Insufficiency: Prognostic Role of Albumin-Bilirubin Grade.

Authors:  Shu-Yein Ho; Chia-Yang Hsu; Po-Hong Liu; Chih-Chieh Ko; Yi-Hsiang Huang; Chien-Wei Su; Rheun-Chuan Lee; Ming-Chih Hou; Teh-Ia Huo
Journal:  Cancers (Basel)       Date:  2020-04-30       Impact factor: 6.639

7.  A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy.

Authors:  Dongdong Zhou; Xiaoli Liu; Xinhui Wang; Fengna Yan; Peng Wang; Huiwen Yan; Yuyong Jiang; Zhiyun Yang
Journal:  BMC Cancer       Date:  2021-03-08       Impact factor: 4.430

8.  A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Yi-Hsiang Huang; Jia-I Liao; Chien-Wei Su; Ming-Chih Hou; Teh-Ia Huo
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

9.  Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters.

Authors:  Sabrina Sidali; Jean-Charles Nault
Journal:  United European Gastroenterol J       Date:  2022-01-08       Impact factor: 4.623

10.  Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model.

Authors:  Chia-Yang Hsu; Yun-Hsuan Lee; Po-Hong Liu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Han-Chieh Lin; Yi-You Chiou; Fa-Yauh Lee; Teh-Ia Huo
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.